| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3335454 | Transfusion and Apheresis Science | 2012 | 4 Pages |
Abstract
Intravenous immunoglobulin (IVIG) is a mainstay of therapy in many disorders. An uncommon adverse side effect is IVIG-related hemolysis. Risk factors for IVIG-related hemolysis have been identified, including high dose IVIG given to non-O blood group recipients with an underlying inflammatory state. IVIG-related hemolysis has been linked to anti-A and anti-B hemagglutinins in the IVIG preparations and may involve both IgG and complement mediated hemolysis. A two-hit mechanism with threshold effect is proposed for IVIG-related hemolysis. Strategies exist to minimize or avoid IVIG-related hemolysis.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Ruth F. Padmore,